Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2024

This Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Ventricular Tachycardia (V-tach or VT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ventricular Tachycardia (V-tach or VT) Understanding

Ventricular Tachycardia (V-tach or VT): Overview

Ventricular tachycardia is characterized as a wide complex (QRS duration greater than 120 milliseconds) tachyarrhythmia at a heart rate greater than 100 beats per minute. It is classified by duration as non-sustained or sustained. Non-sustained ventricular tachycardia is defined as more than 3 beats of ventricular origin at a rate greater than 100 beats per minute that lasts less than 30 seconds in duration. When the rhythm lasts longer than 30 seconds or hemodynamic instability occurs in less than 30 seconds, it is considered sustained ventricular tachycardia. Further classification is made into monomorphic and polymorphic on the basis of QRS morphology. Monomorphic ventricular tachycardia demonstrates a stable QRS morphology from beat to beat while polymorphic ventricular tachycardia has changing or multiform QRS variance from beat to beat. Torsades de pointes is a polymorphic ventricular tachycardia that occurs in the setting of a long QT interval and appears as waxing and waxing QRS amplitude on ECG.

Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ventricular Tachycardia (V-tach or VT) pipeline landscape is provided which includes the disease overview and Ventricular Tachycardia (V-tach or VT) treatment guidelines. The assessment part of the report embraces, in depth Ventricular Tachycardia (V-tach or VT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ventricular Tachycardia (V-tach or VT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ventricular Tachycardia (V-tach or VT) R&D. The therapies under development are focused on novel approaches to treat/improve Ventricular Tachycardia (V-tach or VT).

This segment of the Ventricular Tachycardia (V-tach or VT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ventricular Tachycardia (V-tach or VT) Drugs
ARM210: ARMGO Pharma ARM210 is a small molecule that binds to leaky RyR channels and repairs the leak, as demonstrated in vitro in muscle biopsies from RYR1-RM patients.ARM210 for the treatment of CPVT, a rare form of ventricular tachycardia and sudden death caused by mutations in the ryanodine receptor 2 (RyR2) which controls Ca2+ homeostasis incells.

Ventricular Tachycardia (V-tach or VT): Therapeutic Assessment

This segment of the report provides insights about the Ventricular Tachycardia (V-tach or VT) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ventricular Tachycardia (V-tach or VT)

There are approx. 5+ key companies which are developing the therapies for Ventricular Tachycardia (V-tach or VT). The companies which have their Ventricular Tachycardia (V-tach or VT) drug candidates in the most advanced stage, i.e. Phase II include ARMGO Pharma.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ventricular Tachycardia (V-tach or VT) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ventricular Tachycardia (V-tach or VT): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ventricular Tachycardia (V-tach or VT) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ventricular Tachycardia (V-tach or VT) drugs.

Ventricular Tachycardia (V-tach or VT) Report Insights

• Ventricular Tachycardia (V-tach or VT) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ventricular Tachycardia (V-tach or VT) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ventricular Tachycardia (V-tach or VT) drugs?
• How many Ventricular Tachycardia (V-tach or VT) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ventricular Tachycardia (V-tach or VT)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ventricular Tachycardia (V-tach or VT) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ventricular Tachycardia (V-tach or VT) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Espero BioPharma
• CTP amio Vivasc Therapeutics
• Aladorian - ARMGO Pharma
• RyR2 Research Program

Key Products

• ESP 001
• Vivasc Therapeutics
• ARMGO Pharma
• RyR2 Research Program